Macau Casino Gambli...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$10.09 -0.15 | -1.46%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.05 | 0.58 | 0.98 |
| Price to Sales (TTM) | 6.36 | 4.62 | 1.42 |
| Price to Book (MRQ) | 2.66 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 2.66 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -11.20 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -1.50 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -17.30 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 18.90 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -20.28 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.10 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | -53.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -79.53 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -64.00 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -58.90 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.64 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -60.50 | 5.30 | 7.00 |
| Return on Assets (TTM) | -15.50 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -11.80 | 2.20 | 2.50 |
| Return on Investment (TTM) | -26.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -30.30 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 710,750.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -454,586.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 49.30 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.20 | 0.40 | 0.40 |
Portfolios with ALNY
- Portfolio NameUser Type
- UserThe #1 Growth Fund To Make ...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
- UserHancock Hallock Firm
Latest ALNY Headlines from TheStreet
- 5 Stocks Insiders Love Right Now 02.24.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.15.12 | 02:02 pm
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
- Cramer's 'Mad Money' Recap: Betting Against the Bears (Update 2) 01.03.12 | 06:01 pm
- AK Steel, Applied Materials: New Ratings 02.23.11 | 09:02 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results  Earnings Call Transcript 11.03.10 | 10:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Alnylam Cuts Jobs On Partner Exit 09.24.10 | 07:09 am
- Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.05.10 | 12:08 am
Press Releases for ALNY
- Alnylam Announces Top-Line Results Of Phase IIb Clinical Trial Of ALN-RSV01, An Inhaled RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection - Business Wire 05.30.12 | 06:05 am
- Alnylam And PBL Sign License Agreement For Baulcombe & Hamilton RNAi Patent - Business Wire 05.23.12 | 08:05 am
- Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 04:05 pm
- Alnylam To Webcast Conference Call Discussing First Quarter 2012 Financial Results - Business Wire 04.26.12 | 04:04 pm
- Alnylam To Webcast Presentation At Future Leaders In The Biotech Industry Conference - Business Wire 04.13.12 | 04:04 pm
- Alnylam To Webcast Presentation At 11th Annual Needham Healthcare Conference - Business Wire 03.27.12 | 04:03 pm
- Alnylam Initiates Phase I Clinical Study Of ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) - Business Wire 03.19.12 | 08:03 am
- Alnylam Retains Key Claims For Kinesin Spindle Protein (KSP) RNAi Patent In Interference Proceedings - Business Wire 03.14.12 | 06:03 am
- Alnylam To Webcast Presentation At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 04:03 pm
- Alnylam And The University Of Massachusetts Medical School Announce Tuschl I Patent Upheld In European Opposition Proceedings - Business Wire 03.01.12 | 11:03 am
Partner Headlines for ALNY
- The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases - Zacks 03.28.12 | 09:03 am
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Company News for February 15, 2012 - Corporate Summary - Zacks 02.15.12 | 10:02 am
- Alnylam Pharma Up 8% After Pricing Public Offering - Benzinga 02.15.12 | 09:02 am
- Alnylam Delivers In-Line Numbers - Analyst Blog - Zacks 02.13.12 | 10:02 am
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Alnylam Down to Neutral - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
